Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The proposed study is for a 6 week open-label clinical trial in which Seroquel XR is added to
a selective serotonin reuptake inhibitor (SSRI) medication for the treatment of depressive
and/or anxiety symptoms. Each subject will self-report changes in symptoms, functional
impairment, etc. on a twice daily basis using a handheld computer (HHC) that transmits
real-time symptoms reports to a central database. Each subject will be assessed in-person on
a weekly or biweekly basis during the course of the study.